OncoMatch/Clinical Trials/NCT06662006
Nal-IRI/5-FU/LV Chemotherapy Combined With PD-L1 Inhibitor and Multi-target Anti-angiogenic Small Molecule±SBRT as Second-line Therapy in Metastatic Pancreatic Cancer Patients
Is NCT06662006 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies nal-IRI,5-fu,LV, benmelstobart, anlotinib for advanced metastatic pancreatic cancer.
Treatment: nal-IRI,5-fu,LV, benmelstobart, anlotinib — This study is a single-arm, multi-center, multi-cohort, prospective clinical study initiated by the investigator. The indication of this study is: patients with advanced metastatic pancreatic cancer who have progressed after first-line chemotherapy. Eligible patients will be assigned to liposomal irinotecan (nal-IRI) plus 5-fluorouracil (5-FU)/leucovorin (LV) (nal-IRI/5-FU/LV) combined with benmelstobart and anlotinib ± SBRT. The total sample size for this study is expected to be 56 subjects.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Cancer type
Pancreatic Cancer
Disease stage
Required: Stage IV
Metastatic disease required
advanced metastatic pancreatic cancer; Imaging suggests distant measurable lesions
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Must have received: first-line therapy — advanced/metastatic
Failure of first-line therapy
Cannot have received: fluorouracil
no use of fluorouracil ... in the first-line therapy
Cannot have received: irinotecan
no use of ... irinotecan ... in the first-line therapy
Cannot have received: liposomal irinotecan
no use of ... liposomal irinotecan drugs in the first-line therapy
Cannot have received: second-line or more anti-tumor therapy
Have received second-line or more anti-tumor therapy in the past
Lab requirements
Blood counts
Neutrophil count ≥ 1.5×10^9/L; Hemoglobin ≥ 10 g/dL; Platelet count ≥ 100×10^9/L
Kidney function
Creatinine clearance ≥ 60ml/min
Liver function
Total bilirubin ≤ 1.5× ULN; AST and ALT <1.5× ULN
Neutrophil count ≥ 1.5×10^9/L; Hemoglobin ≥ 10 g/dL; Platelet count ≥ 100×10^9/L; Total bilirubin ≤ 1.5× ULN; AST and ALT <1.5× ULN; Creatinine clearance ≥ 60ml/min
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06662006 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior fluorouracil, irinotecan, liposomal irinotecan disqualifies patients from enrollment.
What disease stage is eligible?
Stage IV is required (metastatic disease required).
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages